Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 2,538 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Like Clear all
Completed Not applicable Interventional

Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound

NCT02902562
View directory record Official record
Conditions
Synovitis, Rheumatoid Arthritis
Interventions
Contrast Enhanced Ultrasound (CEUS), Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 27, 2026, 1:03 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

NCT02950688
View directory record Official record
Conditions
Influenza, Human
Interventions
Seasonal LAIV, Placebo, Wild-type A/California/2009-like Influenza Virus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Intersection Between Loss of Control Eating and Obesity: The Role of Restriction and Food Reinforcement

NCT05177705
View directory record Official record
Conditions
Pediatric Obesity, Nutrition Disorders, Binge Eating, Body Weight
Interventions
Restricted access task, Structured Intake
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
8 Years to 11 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Varenicline OTC Trial on Efficacy and Safety

NCT03557294
View directory record Official record
Conditions
Tobacco Dependence, Withdrawal Symptoms, Smoking Cessation
Interventions
1.0mg Varenicline b.i.d., 0.5mg Varenicline b.i.d., 0.0mg placebo Varenicline b.i.d.
Drug
Lead sponsor
Arizona State University
Other
Eligibility
21 Years and older
Enrollment
313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Burbank, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Copper IUD Treatment Observation Study

NCT02519231
View directory record Official record
Conditions
Menorrhagia
Interventions
Naproxen, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 27, 2026, 1:03 PM EDT
Terminated Not applicable Interventional

Airway Secretion Clearance in Cystic Fibrosis

NCT00839644
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
High frequency chest wall oscillation, Oscillatory Positive Expiratory Pressure, PD&P: Postural drainage and percussion
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 27, 2026, 1:03 PM EDT
Recruiting Phase 1 Interventional

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

NCT02254863
View directory record Official record
Conditions
Adrenoleukodystrophy, Batten Disease, Mucopolysaccharidosis II, Leukodystrophy, Globoid Cell, Leukodystrophy, Metachromatic, Neimann Pick Disease, Pelizaeus-Merzbacher Disease, Sandhoff Disease, Tay-Sachs Disease, Brain Diseases, Metabolic, Inborn, Alpha-Mannosidosis, Sanfilippo Mucopolysaccharidoses
Interventions
DUOC-01
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
1 Week to 22 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 27, 2026, 1:03 PM EDT
Withdrawn Phase 2 Interventional

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

NCT05216614
View directory record Official record
Conditions
COVID-19, Olfactory Disorder, Parosmia
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet Induced Weight Loss to Reduce Inflammation in Obese Women

NCT01699906
View directory record Official record
Conditions
Obesity
Interventions
Diet regimen to induce weight loss
Other
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

NCT01272232
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

NCT00319748
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer
Interventions
852A
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 27, 2026, 1:03 PM EDT
Not yet recruiting Phase 3 Interventional

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

NCT07881432
View directory record Official record
Conditions
Obesity
Interventions
eloralintide and tirzepatide, Eloralintide, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
55
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 1:03 PM EDT
Recruiting Phase 2 Interventional

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

NCT05822609
View directory record Official record
Conditions
Diabetic Kidney Disease, Type 1 Diabetes
Interventions
Semaglutide, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Aurora, Colorado • Seattle, Washington • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 27, 2026, 1:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Data Collection for Activity, Adiposity, and Appetite in Adolescents

NCT03157063
View directory record Official record
Conditions
Physical Activity, Sedentary Lifestyle, Metabolism, Energy Balance
Interventions
Data Collection Procedures
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
14 Years to 18 Years · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 27, 2026, 1:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty

NCT05845021
View directory record Official record
Conditions
Osteoporosis, Arthroplasty Complications, Fragility Fracture
Interventions
Surgeon-Initiated Bone Health Referral Pathway
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

GLP1R Polymorphisms and Response to GLP1

NCT00588380
View directory record Official record
Conditions
Diabetes
Interventions
GLP-1
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobilized Psychoeducation and Skills Based Intervention (Pep-Pal) for Caregivers of Patients With Advanced Illness

NCT03002896
View directory record Official record
Conditions
Distress, Anxiety, Depression
Interventions
Pep-Pal, Treatment as Usual
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Not applicable Interventional Results available

Reducing Falls With RENEW in Older Adults Who Have Fallen

NCT01080196
View directory record Official record
Conditions
Muscle Atrophy, Physical Deconditioning
Interventions
RENEW
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
65 Years to 95 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Not applicable Interventional Results available

Atrial Fibrillation Health Literacy and Information Technology Trial in Rural Pennsylvania Counties

NCT04076020
View directory record Official record
Conditions
Atrial Fibrillation, Familial Atrial Fibrillation, Arrhythmia, Cardiac, Heart Diseases, Pathologic Processes
Interventions
Relational agent/AliveCor Kardia - Intervention, Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 27, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

NCT01137682
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 27, 2026, 1:03 PM EDT
Completed No phase listed Observational

Development of Predictive Biomarkers

NCT03423862
View directory record Official record
Conditions
Type1diabetes
Interventions
Mixed Meal Tolerance Test
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 27, 2026, 1:03 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

NCT05729568
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 27, 2026, 1:03 PM EDT
Recruiting Phase 2 Interventional

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

NCT07527910
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Tirzepatide, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Tucson, Arizona • Coronado, California • Pasadena, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 1:03 PM EDT